XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventory, Net
 9 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
Inventory, Net Inventory, Net
All of the Company's inventory relates to the manufacturing of MARGENZA. The following table sets forth the Company's net inventory (in thousands):
September 30, 2022December 31, 2021
Work in process$209 $3,929 
Finished goods877 459 
Total inventory, net$1,086 $4,388 
Prior to U.S. Food and Drug Administration (FDA) approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of September 30, 2022 and December 31, 2021 is net of a reserve of $4.9 million and $2.0 million, respectively, for unsaleable inventory. These reserves are reflected in cost of product sales during the period they are recorded.